GHRP-6 5mg

Name: GHRP-6 5mg
SKU: PL-5MG-PF01
Price: 33.00 USD
Availability: InStock

Brands PeptideLion

$33.00

out of stock

Sku:

PL-5MG-PF01

Brands: PeptideLion

Description

Overview:

Growth hormone-releasing peptide 6 (GHRP-6) (developmental code name SKF-110679), also known as growth hormone-releasing hexapeptide, is one of several synthetic met-enkephalin analogues that include unnatural D-amino acids, were developed for their growth hormone-releasing activity and are called growth hormone secretagogues. They lack opioid activity but are potent stimulators of growth hormone (GH) release. These secretagogues are distinct from growth hormone releasing hormone (GHRH) in that they share no sequence relation and derive their function through activation of a completely different receptor. This receptor was originally called the growth hormone secretagogue receptor (GHSR), but due to subsequent discoveries, the hormone ghrelin is now considered the receptor’s natural endogenous ligand, and it has been renamed as the ghrelin receptor. Therefore, these GHSR agonists act as synthetic ghrelin mimetics.

GHRP-6 Effects:

Increased collagen production
Better repair of internal organs
Increased healing capacity
Increased energy
Improved sleep
Increase in lean body mass
Reduced body fat

Scientific Information:

Growth hormone releasing peptide (GHRP-6) is a synthetic hexapeptide which specifically stimulates secretion of growth hormone (GH) by pituitary somatotrophs. The precise intracellular mechanism by which this is achieved has not been deciphered although it is known to involve protein kinase C (PKC) and Ca2+ but to be cAMP-independent. We have used cell cultures of human pituitary somatotrophinomas to demonstrate powerful effects of GHRP-6 on membrane phosphatidylinositol (PI) turnover, a second messenger system which leads to activation of PKC and mobilisation of intracellular Ca2+ reserves. Incubation of somatotrophinoma cells with GHRP-6 led to a dose-dependent stimulation of rate of PI turnover. GH secretion was increased in parallel. Effects were discernable after only 15 minutes incubation and rose to a maximum at 2 hours. PI turnover was stimulated by GHRP-6 in 8 of 8 tumours examined, effects ranging from 2.1 – 7.9 fold increases. Stimulation of GH secretion by GHRP-6 was independent of presence of gsp oncogenes, emphasising the cAMP-independent nature of its effects. These results provide evidence that the GH-stimulatory effects of GHRP-6 are achieved through activation of the PI second messenger system and thus support earlier findings that PKC and Ca2+ play central roles in mediating the effects of GHRP-6.

The family of peptidyl growth hormone (GH) secretagogues with broad cytoprotective properties came to light by the American endocrinologist Cyril Bowers, who observed that chemical analogs of enkephalin amide showed GH-releasing activity upon their incorporation to pituitary cultures. GHRP-6 (His-DTrp-Ala-Trp-DPhe-Lys-NH2) appeared as the first in-line synthetic peptide that specifically elicited GH dosage-related release in vitro and in vivo.

GHRP-6 exhibits a potent cytoprotective effect, extending tissue viability during acute ischemia/reperfusion episodes in different organs (e.g. small bowel, liver, kidneys). This peptide has also shown antioxidant activity in preclinical experimental models, and may partially contribute to reduce myocardial ischemic damage. Thus, pathologies associated with ischemia or some types of tissue damage may potentially benefit from treatment with this promising therapeutic candidate.

Research Highlights:

Based on the potential benefits of the growth hormone releasing peptide (GHRP)-6 on muscle functions, newly synthesized GHRP-6-biotin conjugate was tested on cultured myoblast cells. Increased expression of myogenic marker proteins was observed in GHRP-6-biotin conjugate treated cells. In addition, increased expression levels of insulin-like growth factor-1 and collagen type I were also noted. Furthermore, GHRP-6-biotin conjugate treated cells had increased metabolic activity as indicated by increased concentration of energy metabolites such as ATP, lactate, and increased enzymatic activity of lactate dehydrogenase and creatine kinase. Lastly, binding protein analysis suggested few candidate proteins, including desmin, actin, and zinc finger protein 691 as potential targets for GHRP-6-biotin conjugate action. These results suggest that the newly synthesized GHRP-6-biotin conjugate has myogenic stimulating activity through, at least in part, by stimulating collagen type I synthesis and several key proteins. Practical application of GHRP-6-biotin conjugate could be used for improving muscle conditions.